8-K: Viatris Reports Strong Second Quarter Results, Raises Full-Year New Product Revenue Outlook

Viatris announced strong second-quarter 2024 financial results, including total revenues of $3.8 billion and a 2% operational revenue growth on a divestiture-adjusted basis, and raised its full-year new product revenue outlook.

Summary

• Viatris reported total revenues of $3.8 billion for the second quarter of 2024.
• The company achieved operational revenue growth of approximately 2% on a divestiture-adjusted basis.
• New product revenues for the quarter were $210 million.
• U.S. GAAP net loss was $326 million, while adjusted EBITDA grew by approximately 2% to $1.2 billion on a divestiture-adjusted basis.
• U.S. GAAP diluted EPS was a loss of $0.27 per share, but adjusted EPS grew by approximately 3% to $0.69 per share on a divestiture-adjusted basis.
• The company has completed its divestitures, marking an inflection point towards accelerated growth and shareholder return.
• Viatris raised its 2024 full-year new product revenue range to $500 million to $600 million.
• The company expects 2024 full-year total revenue growth of approximately 2% on a divestiture-adjusted operational basis.
• U.S. GAAP total revenues for 2024 are estimated to be between $14.60 and $15.10 billion, with a midpoint of $14.85 billion, representing a full-year decrease of approximately 4%.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the strong operational growth, new product performance, and raised outlook, but tempered by the U.S. GAAP net loss and revenue decline. The completion of divestitures and focus on future growth are encouraging.

Positives

• Viatris demonstrated strong operational revenue growth across all segments, including Greater China.
• The company's new product launches are performing well, contributing significantly to revenue.
• The completion of divestitures is expected to strengthen the company's financial position.
• Viatris is focused on a strategy with three main pillars: a diversified base business, financial strength, and an expanding innovative portfolio.
• The company generated $426 million in free cash flow, excluding transaction costs, and paid down $800 million of debt.
• Viatris was named to TIME's World's Most Sustainable Companies 2024 List.

Negatives

• Viatris reported a U.S. GAAP net loss of $326 million for the second quarter.
• U.S. GAAP diluted EPS was a loss of $0.27 per share.
• Total revenues declined by approximately 3% on a U.S. GAAP basis.
• U.S. GAAP net earnings declined from $264 million to a loss of $326 million.
• U.S. GAAP diluted EPS declined from $0.22 per share to a loss of $0.27 per share.
• U.S. GAAP total revenues for 2024 are estimated to decrease by approximately 4%.

Risks

• The company's future results may be affected by the possibility that it may not realize the intended benefits of its strategic initiatives.
• There is a risk that Viatris may be unable to achieve expected benefits from divestitures, acquisitions, or restructuring programs.
• The company's performance could be impacted by changes in healthcare and pharmaceutical regulations.
• There are risks associated with the company's global operations, including supply chain disruptions and currency fluctuations.
• The company faces competition, which could lead to decreased sales or revenues.
• Uncertainties regarding future demand, pricing, and reimbursement for the company's products could affect results.

Future Outlook

Viatris expects continued momentum in the business and is well-positioned for a strong second half of the year. The company anticipates that its three strategic pillars will enable accelerated growth and shareholder return. The company expects to be at the midpoint of the August 8, 2024, guidance ranges.

Management Comments

• Scott A. Smith, CEO, stated that the company delivered divestiture-adjusted operational revenue growth across all segments, including strong growth in Greater China.
• Scott A. Smith, CEO, believes the company is at an inflection point with divestitures behind them and a strong foundation to build on.
• Doretta Mistras, CFO, noted that the company's solid fundamentals drove the second quarter results.
• Doretta Mistras, CFO, highlighted the approximately 2% growth in divestiture-adjusted operational revenue and the growth in adjusted EBITDA and adjusted EPS.

Industry Context

This announcement reflects Viatris's ongoing efforts to streamline its operations through divestitures and focus on core growth areas. The company's emphasis on new product launches and operational efficiency aligns with broader industry trends in the pharmaceutical sector, where companies are increasingly looking to diversify their portfolios and enhance profitability.

Comparison to Industry Standards

• Viatris's 2% divestiture-adjusted operational revenue growth is a positive sign, but it is important to compare this to peers like Teva Pharmaceuticals and Mylan (prior to the merger with Upjohn) to assess its relative performance.
• The adjusted EBITDA growth of 2% is modest and should be compared to the growth rates of other generic and branded pharmaceutical companies such as Sandoz and Hikma Pharmaceuticals.
• The new product revenue of $210 million is a key driver of growth and should be benchmarked against the new product launch success of companies like Sun Pharma and Lupin.
• The company's debt reduction of $800 million is a positive step, but its overall debt levels should be compared to industry averages to assess its financial health.
• The company's focus on sustainability, as recognized by TIME, is a growing trend in the industry and should be compared to the sustainability initiatives of other major pharmaceutical companies.

Stakeholder Impact

• Shareholders may view the results positively due to the operational growth and raised outlook, but the U.S. GAAP net loss may cause concern.
• Employees may be impacted by the ongoing restructuring and strategic changes.
• Customers will likely benefit from the company's focus on new product launches and access to medicines.
• Suppliers may be affected by the company's divestitures and changes in its supply chain.
• Creditors may view the debt reduction positively, but will also monitor the company's overall financial health.

Next Steps

• Viatris will host a conference call and live webcast to review the Q2 2024 financial results.
• The company will continue to focus on its three strategic pillars: a diversified base business, financial strength, and an expanding innovative portfolio.
• Viatris will continue to execute its strategy to accelerate growth and shareholder return.

Key Dates

Keywords

Viatris, Financial Results, Second Quarter, Revenue Growth, Divestitures, New Products, Adjusted EBITDA, Adjusted EPS, Pharmaceuticals, Generics, Brands